open access

Vol 20, No 6 (2013)
Original articles
Published online: 2013-12-11
Get Citation

Early detection of anthracycline-induced cardiotoxicity using two-dimensional speckle tracking echocardiography

Yu Kang, Leilei Cheng, Lin Li, Haiyan Chen, Minmin Sun, Zheng Wei, Cuizhen Pan, Xianhong Shu
DOI: 10.5603/CJ.2013.0158
·
Cardiol J 2013;20(6):592-599.

open access

Vol 20, No 6 (2013)
Original articles
Published online: 2013-12-11

Abstract

Background: To examine the subclinical myocardial injury shortly after epirubicin exposure in asymptomatic patients with large B-cell non-Hodgkin lymphoma using 2-dimensional (2D)speckle tracking echocardiography.

Methods: Sixty-seven patients aged 52.58 ± 13.86 years with large B-cell non-Hodgkin lymphoma treated with epirubicin were studied. Echocardiography was performed at baseline and 1 day after completion of the therapy. Global and regional longitudinal (LS), circumferential (CS) and radial strain (RS), standard deviation of time to peak LS (TLS-SD), CS (TCS-SD), RS(TRS-SD) were calculated using 2D speckle tracking echocardiography.

Results: Despite normal left ventricular ejection fraction, global LS (–18.30 ± 1.87% vs.–16.18 ± 1.92%; p < 0.01), CS (–20.37 ± 2.89% vs. –18.25 ± 2.40%, p < 0.01) and RS (39.95 ± 5.79% vs. 36.15 ± 5.79%, p < 0.01), were remarkably reduced compared to baseline values. However, TLS-SD, TCS-SD and TRS-SD showed no significant difference after epirubicin exposure. Hypertension was an independent predictor of reduction of global LS, CS and RS.

Conclusions: Subtle abnormalities in myocardial systolic function were present in asymptomatic patients shortly after anthracycline exposure, which could be detected by 2D speckle tracking echocardiography.

Abstract

Background: To examine the subclinical myocardial injury shortly after epirubicin exposure in asymptomatic patients with large B-cell non-Hodgkin lymphoma using 2-dimensional (2D)speckle tracking echocardiography.

Methods: Sixty-seven patients aged 52.58 ± 13.86 years with large B-cell non-Hodgkin lymphoma treated with epirubicin were studied. Echocardiography was performed at baseline and 1 day after completion of the therapy. Global and regional longitudinal (LS), circumferential (CS) and radial strain (RS), standard deviation of time to peak LS (TLS-SD), CS (TCS-SD), RS(TRS-SD) were calculated using 2D speckle tracking echocardiography.

Results: Despite normal left ventricular ejection fraction, global LS (–18.30 ± 1.87% vs.–16.18 ± 1.92%; p < 0.01), CS (–20.37 ± 2.89% vs. –18.25 ± 2.40%, p < 0.01) and RS (39.95 ± 5.79% vs. 36.15 ± 5.79%, p < 0.01), were remarkably reduced compared to baseline values. However, TLS-SD, TCS-SD and TRS-SD showed no significant difference after epirubicin exposure. Hypertension was an independent predictor of reduction of global LS, CS and RS.

Conclusions: Subtle abnormalities in myocardial systolic function were present in asymptomatic patients shortly after anthracycline exposure, which could be detected by 2D speckle tracking echocardiography.

Get Citation

Keywords

two-dimensional speckle tracking echocardiography, anthracycline-induced cardiotoxicity, left ventricular systolic function

About this article
Title

Early detection of anthracycline-induced cardiotoxicity using two-dimensional speckle tracking echocardiography

Journal

Cardiology Journal

Issue

Vol 20, No 6 (2013)

Pages

592-599

Published online

2013-12-11

DOI

10.5603/CJ.2013.0158

Bibliographic record

Cardiol J 2013;20(6):592-599.

Keywords

two-dimensional speckle tracking echocardiography
anthracycline-induced cardiotoxicity
left ventricular systolic function

Authors

Yu Kang
Leilei Cheng
Lin Li
Haiyan Chen
Minmin Sun
Zheng Wei
Cuizhen Pan
Xianhong Shu

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl